Clinical Trials Logo
  1. Home
  2. Gastroesophageal Junction Cancer
  3. NCT02027948

A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer

Gastroesophageal Junction Cancer Clinical Trial

Official title:
A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer

Clinical Trial Summary

Patients with esophageal and gastroesophageal junction (GEJ) cancer often have weight loss, swallowing problems, and poor appetite. This may affect their ability to tolerate cancer treatment. The purpose of this study is to see if the researchers can apply a set of nutrition guidelines designed specifically for patients with cancer who are older than 65 years of age. The questions will allow them to assess the nutritional status and make appropriate referrals. If the patients are having swallowing problems or losing weight, the researchers want to address the nutritional problems early in the course of their treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02027948
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Completed
Phase N/A
Start date December 23, 2013
Completion date March 1, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT01747707 - Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer Phase 2
Active, not recruiting NCT03221426 - Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Phase 3
Completed NCT02178956 - A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Phase 3
Active, not recruiting NCT02872116 - Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Phase 3
Completed NCT02538562 - Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea N/A
Recruiting NCT05322577 - A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. Phase 1
Terminated NCT01813253 - Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer Phase 3
Recruiting NCT06346392 - AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 Phase 3
Recruiting NCT06250894 - Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction Phase 2
Active, not recruiting NCT04276493 - Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab Phase 1/Phase 2
Terminated NCT02726399 - Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer Phase 2
Recruiting NCT05395780 - A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer Phase 2
Completed NCT02661971 - FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Phase 2/Phase 3
Completed NCT02581462 - FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer Phase 2/Phase 3
Completed NCT00917462 - Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer Phase 2
Recruiting NCT05187182 - CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer Phase 1
Not yet recruiting NCT06411171 - Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: Phase 3